

Navigating Bispecific Therapies in Multiple Myeloma: Roadmap for Onboarding and Operationalization

A panel of academic and community practice pharmacists with experience using BsAb was convened to provide recommendations for operationalizing and managing BsAb therapy




Institutional integration & operationalization

i P&T workflow

i EHR & REMS

i Financial considerations



Patient selection

i Inpatient

i Outpatient



Key stakeholders¹

- Physicians
- Advanced practice providers
- Pharmacists
- Nursing
- Social work
- Critical care staff
- Emergency department staff
- Administrators

i Additional considerations



Administration

i Drug admin/monitoring

i Caregiver considerations



Transitions

i Patient transitions



Management

i CRS/ICANS
i Other AEs
i GPRC5D AEs

AE, adverse event; BsAb, bispecific antibody; CRS, cytokine release syndrome; EHR, electronic health record; GPRC5D, G protein–coupled receptor family C group 5 member D; ICANS, Immune effector cell-associated neurotoxicity syndrome; MM, multiple myeloma; P&T, Pharmacy & Therapeutics; REMS, risk evaluation and mitigation strategy.

1. Mahmoudjafari Z, et al. Sept 2024; online first. Available here: <https://doi.org/10.6004/jadpro.2024.15.8.15>



Please click the *i* icons for additional information.

Johnson & Johnson

Confidential and proprietary information. J&J does not endorse or promote use of any specific guidelines. These are provided for information purpose only, in response to a medial information request.
US-SFM-6773 September 2026. © Johnson & Johnson and its affiliates 2026. Provided in response to a medical information request; for informational purposes only; no further use permitted. Capitalized product names are trademarks of Johnson & Johnson and its affiliates.